title: Drug design with a new transition state analog of the hydrated carbonyl: silicon-based inhibitors of the HIV protease.
abstract: BACKGROUND
  Silicon is the element most similar to carbon, and bioactive organosilanes have therefore been of longstanding interest. Design of bioactive organosilanes has often involved a systematic replacement of a bioactive molecule's stable carbon atoms with silicon. Silanediols, which are best known as unstable precursors of the robust and ubiquitous silicone polymers, have the potential to mimic an unstable carbon, the hydrated carbonyl. As a bioisostere of the tetrahedral intermediate of amide hydrolysis, a silanediol could act as a transition state analog inhibitor of protease enzymes.
  
  
  RESULTS
  Silanediol analogs of a carbinol-based inhibitor of the HIV protease were prepared as single enantiomers, with up to six stereogenic centers. As inhibitors of this aspartic protease, the silanediols were nearly equivalent to both their carbinol analogs and indinavir, a current treatment for AIDS, with low nanomolar K(i) values. IC(90) data from a cell culture assay mirrored the K(i) data, demonstrating that the silanediols can also cross cell membranes and deliver their antiviral effects.
  
  
  CONCLUSIONS
  In their first evaluation as inhibitors of an aspartic protease, silanediol peptidomimetics have been found to be nearly as potent as currently available pharmaceutical agents, in enzyme and cell protection assays. These neutral, cell-permeable transition state analogs therefore provide a novel foundation for the design of therapeutic agents.
authors.affiliation: Department of Chemistry, State University of New York, Stony Brook, NY 11794-3400, USA.
authors.forename: C A
authors.initials: CA
authors.lastname: Chen
authors.forename: S M
authors.initials: SM
authors.lastname: Sieburth
authors.forename: A
authors.initials: A
authors.lastname: Glekas
authors.forename: G W
authors.initials: GW
authors.lastname: Hewitt
authors.forename: G L
authors.initials: GL
authors.lastname: Trainor
authors.forename: S
authors.initials: S
authors.lastname: Erickson-Viitanen
authors.forename: S S
authors.initials: SS
authors.lastname: Garber
authors.forename: B
authors.initials: B
authors.lastname: Cordova
authors.forename: S
authors.initials: S
authors.lastname: Jeffry
authors.forename: R M
authors.initials: RM
authors.lastname: Klabe
mesh_terms: D002478:Cells, Cultured; D015195:Drug Design; D017320:HIV Protease Inhibitors / Q000737:chemistry* / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008958:Models, Molecular; D017646:Organosilicon Compounds / Q000737:chemistry* / Q000494:pharmacology*
chemical_list: D017320:HIV Protease Inhibitors; D017646:Organosilicon Compounds